Cargando…

Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy

Although high body mass index (BMI) was reported to associate with a better prognosis for metastatic renal cell cancer (mRCC) patients receiving anti-vascular endothelial growth factor (anti-VEGF) therapy, it is an imperfect proxy for the body composition, especially in Asian patients with a lower B...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Kang, Li, Zhen, Liu, Huiming, Tian, Xi, Wang, Jun, Wu, Yi, Xiong, Longbin, Zou, Xiangpeng, Peng, Yulu, Zhou, Zhaohui, Zhou, Fangjian, Yu, Chunping, Luo, Junhang, Zhang, Hailiang, Dong, Pei, Zhang, Zhiling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412489/
https://www.ncbi.nlm.nih.gov/pubmed/36014894
http://dx.doi.org/10.3390/nu14163388
_version_ 1784775506704465920
author Ning, Kang
Li, Zhen
Liu, Huiming
Tian, Xi
Wang, Jun
Wu, Yi
Xiong, Longbin
Zou, Xiangpeng
Peng, Yulu
Zhou, Zhaohui
Zhou, Fangjian
Yu, Chunping
Luo, Junhang
Zhang, Hailiang
Dong, Pei
Zhang, Zhiling
author_facet Ning, Kang
Li, Zhen
Liu, Huiming
Tian, Xi
Wang, Jun
Wu, Yi
Xiong, Longbin
Zou, Xiangpeng
Peng, Yulu
Zhou, Zhaohui
Zhou, Fangjian
Yu, Chunping
Luo, Junhang
Zhang, Hailiang
Dong, Pei
Zhang, Zhiling
author_sort Ning, Kang
collection PubMed
description Although high body mass index (BMI) was reported to associate with a better prognosis for metastatic renal cell cancer (mRCC) patients receiving anti-vascular endothelial growth factor (anti-VEGF) therapy, it is an imperfect proxy for the body composition, especially in Asian patients with a lower BMI. The role of visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and perirenal fat thickness (PRFT) in mRCC patients was still unknown. Therefore, a multicenter retrospective study of 358 Chinese mRCC patients receiving anti-VEGF therapy was conducted and their body composition was measured via computed tomography. We parameterized VAT, SAT and PRFT according to their median value and BMI according to Chinese criteria (overweight: BMI ≥ 24). We found VAT, SAT, and PRFT (all p < 0.05) but not BMI, significantly associated with overall survival (OS) and progression-free survival (PFS). Multivariate Cox analysis identified PRFT was the independent predictor of OS and PFS, and IMDC expanded with PRFT showed the highest C-index in predicting OS (OS:0.71) compared with VAT, SAT, and BMI. PRFT could increase the area under the curve of the traditional International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model in OS (70.54% increase to 74.71%) and PFS (72.22% increase to 75.03%). PRFT was introduced to improve the IMDC model and PRFT-modified IMDC demonstrated higher AIC in predicting OS and PFS compared with the traditional IMDC model. Gene sequencing analysis (n = 6) revealed that patients with high PRFT had increased angiogenesis gene signatures (NES = 1.46, p = 0.04) which might explain why better drug response to anti-VEGF therapy in mRCC patients with high PRFT. The main limitation is retrospective design. This study suggests body composition, especially PRFT, is significantly associated with prognosis in Chinese mRCC patients receiving anti-VEGF therapy. PRFT-modified IMDC model proposed in this study has better clinical predictive value.
format Online
Article
Text
id pubmed-9412489
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94124892022-08-27 Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy Ning, Kang Li, Zhen Liu, Huiming Tian, Xi Wang, Jun Wu, Yi Xiong, Longbin Zou, Xiangpeng Peng, Yulu Zhou, Zhaohui Zhou, Fangjian Yu, Chunping Luo, Junhang Zhang, Hailiang Dong, Pei Zhang, Zhiling Nutrients Article Although high body mass index (BMI) was reported to associate with a better prognosis for metastatic renal cell cancer (mRCC) patients receiving anti-vascular endothelial growth factor (anti-VEGF) therapy, it is an imperfect proxy for the body composition, especially in Asian patients with a lower BMI. The role of visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and perirenal fat thickness (PRFT) in mRCC patients was still unknown. Therefore, a multicenter retrospective study of 358 Chinese mRCC patients receiving anti-VEGF therapy was conducted and their body composition was measured via computed tomography. We parameterized VAT, SAT and PRFT according to their median value and BMI according to Chinese criteria (overweight: BMI ≥ 24). We found VAT, SAT, and PRFT (all p < 0.05) but not BMI, significantly associated with overall survival (OS) and progression-free survival (PFS). Multivariate Cox analysis identified PRFT was the independent predictor of OS and PFS, and IMDC expanded with PRFT showed the highest C-index in predicting OS (OS:0.71) compared with VAT, SAT, and BMI. PRFT could increase the area under the curve of the traditional International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model in OS (70.54% increase to 74.71%) and PFS (72.22% increase to 75.03%). PRFT was introduced to improve the IMDC model and PRFT-modified IMDC demonstrated higher AIC in predicting OS and PFS compared with the traditional IMDC model. Gene sequencing analysis (n = 6) revealed that patients with high PRFT had increased angiogenesis gene signatures (NES = 1.46, p = 0.04) which might explain why better drug response to anti-VEGF therapy in mRCC patients with high PRFT. The main limitation is retrospective design. This study suggests body composition, especially PRFT, is significantly associated with prognosis in Chinese mRCC patients receiving anti-VEGF therapy. PRFT-modified IMDC model proposed in this study has better clinical predictive value. MDPI 2022-08-18 /pmc/articles/PMC9412489/ /pubmed/36014894 http://dx.doi.org/10.3390/nu14163388 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ning, Kang
Li, Zhen
Liu, Huiming
Tian, Xi
Wang, Jun
Wu, Yi
Xiong, Longbin
Zou, Xiangpeng
Peng, Yulu
Zhou, Zhaohui
Zhou, Fangjian
Yu, Chunping
Luo, Junhang
Zhang, Hailiang
Dong, Pei
Zhang, Zhiling
Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy
title Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy
title_full Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy
title_fullStr Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy
title_full_unstemmed Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy
title_short Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy
title_sort perirenal fat thickness significantly associated with prognosis of metastatic renal cell cancer patients receiving anti-vegf therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412489/
https://www.ncbi.nlm.nih.gov/pubmed/36014894
http://dx.doi.org/10.3390/nu14163388
work_keys_str_mv AT ningkang perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy
AT lizhen perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy
AT liuhuiming perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy
AT tianxi perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy
AT wangjun perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy
AT wuyi perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy
AT xionglongbin perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy
AT zouxiangpeng perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy
AT pengyulu perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy
AT zhouzhaohui perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy
AT zhoufangjian perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy
AT yuchunping perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy
AT luojunhang perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy
AT zhanghailiang perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy
AT dongpei perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy
AT zhangzhiling perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy